Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma announces 1-for-15 reverse stock split effective September 28, 2026

Neutral Impact 3 of 5 shareholder Written later

Matinas BioPharma's board approved a one-for-fifteen reverse stock split of its common stock, which takes effect at 12:01 a.m. Eastern Time on September 28, 2026, with shares trading on a split-adjusted basis under the symbol MTNB. The filing says each stockholder's ownership percentage and voting power will remain essentially unchanged, and the company states there is no assurance the split will keep its shares listed on the NYSE American.

Key points

  • Reverse split ratio: one-for-fifteen (1:15), approved under authority granted by stockholders on June 23, 2025
  • Effective date: 12:01 a.m. Eastern Time on September 28, 2026; new CUSIP number 576810 402
  • Fractional shares will be replaced by a proportional cash payment; holders in brokerage accounts need not act
  • The company states there can be no assurance the split will enable it to maintain its NYSE American listing

The filing

CompanyMatinas BioPharma Holdings, Inc. (MTNB)
Form8-K, current report
Filed with the SECSep 16, 2026, 5:15 PM ET
Accession number0001493152-26-042954

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.